Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease

Jung Hyun Jo, Soo Jung Park, JaeHee Cheon, Tae Il Kim, Won Ho Kim

Research output: Contribution to journalArticle

Abstract

Background and Aims: Many patients with intestinal Behçet's disease (BD) still suffer from gastrointestinal symptoms despite the disease being in endoscopic or radiological remission. Previous studies report that small intestinal bacterial overgrowth (SIBO) can be associated with inflammatory bowel disease. However, there have been no reports about SIBO in patients with intestinal BD. We sought to identify the frequency of SIBO in patients with inactive intestinal BD by hydrogen breath test (HBT) and to investigate the efficacy of rifaximin as a treatment for SIBO. Methods: Twenty-five patients with intestinal BD who had gastrointestinal symptoms even in endoscopic or radiological remission status were enrolled between January 2012 and January 2016. The patients filled out a questionnaire regarding their subjective gastrointestinal symptoms and took an HBT. Patients with positive HBT results were recommended to take 800-mg rifaximin daily for 14 days. Results: Nine patients (9/25, 36%) had a positive HBT test. Eight (8/9, 88.9%) were women, and their mean age was 48.7 years. The most common symptom was abdominal distension (8/9, 88.9%), followed by abdominal discomfort (6/9, 66.7%). Rifaximin was prescribed to the nine patients with positive HBT, but two patients refused to take the medication. Four weeks later, six of the seven patients taking rifaximin (85.7%) reported symptom improvement, and none of them reported adverse events. Conclusions: More than one-third of the patients with inactive intestinal BD who had gastrointestinal symptoms were accompanied by SIBO using HBT. Rifaximin might be an effective and safe drug to treat these patients.

Original languageEnglish
Pages (from-to)375-379
Number of pages5
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume33
Issue number2
DOIs
Publication statusPublished - 2018 Feb 1

Fingerprint

Intestinal Diseases
rifaximin
Breath Tests
Hydrogen
Inflammatory Bowel Diseases

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{36f95230363b4653b04085a1eaf62899,
title = "Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Beh{\cc}et's disease",
abstract = "Background and Aims: Many patients with intestinal Beh{\cc}et's disease (BD) still suffer from gastrointestinal symptoms despite the disease being in endoscopic or radiological remission. Previous studies report that small intestinal bacterial overgrowth (SIBO) can be associated with inflammatory bowel disease. However, there have been no reports about SIBO in patients with intestinal BD. We sought to identify the frequency of SIBO in patients with inactive intestinal BD by hydrogen breath test (HBT) and to investigate the efficacy of rifaximin as a treatment for SIBO. Methods: Twenty-five patients with intestinal BD who had gastrointestinal symptoms even in endoscopic or radiological remission status were enrolled between January 2012 and January 2016. The patients filled out a questionnaire regarding their subjective gastrointestinal symptoms and took an HBT. Patients with positive HBT results were recommended to take 800-mg rifaximin daily for 14 days. Results: Nine patients (9/25, 36{\%}) had a positive HBT test. Eight (8/9, 88.9{\%}) were women, and their mean age was 48.7 years. The most common symptom was abdominal distension (8/9, 88.9{\%}), followed by abdominal discomfort (6/9, 66.7{\%}). Rifaximin was prescribed to the nine patients with positive HBT, but two patients refused to take the medication. Four weeks later, six of the seven patients taking rifaximin (85.7{\%}) reported symptom improvement, and none of them reported adverse events. Conclusions: More than one-third of the patients with inactive intestinal BD who had gastrointestinal symptoms were accompanied by SIBO using HBT. Rifaximin might be an effective and safe drug to treat these patients.",
author = "Jo, {Jung Hyun} and Park, {Soo Jung} and JaeHee Cheon and Kim, {Tae Il} and Kim, {Won Ho}",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/jgh.13855",
language = "English",
volume = "33",
pages = "375--379",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "2",

}

Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease. / Jo, Jung Hyun; Park, Soo Jung; Cheon, JaeHee; Kim, Tae Il; Kim, Won Ho.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 33, No. 2, 01.02.2018, p. 375-379.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease

AU - Jo, Jung Hyun

AU - Park, Soo Jung

AU - Cheon, JaeHee

AU - Kim, Tae Il

AU - Kim, Won Ho

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background and Aims: Many patients with intestinal Behçet's disease (BD) still suffer from gastrointestinal symptoms despite the disease being in endoscopic or radiological remission. Previous studies report that small intestinal bacterial overgrowth (SIBO) can be associated with inflammatory bowel disease. However, there have been no reports about SIBO in patients with intestinal BD. We sought to identify the frequency of SIBO in patients with inactive intestinal BD by hydrogen breath test (HBT) and to investigate the efficacy of rifaximin as a treatment for SIBO. Methods: Twenty-five patients with intestinal BD who had gastrointestinal symptoms even in endoscopic or radiological remission status were enrolled between January 2012 and January 2016. The patients filled out a questionnaire regarding their subjective gastrointestinal symptoms and took an HBT. Patients with positive HBT results were recommended to take 800-mg rifaximin daily for 14 days. Results: Nine patients (9/25, 36%) had a positive HBT test. Eight (8/9, 88.9%) were women, and their mean age was 48.7 years. The most common symptom was abdominal distension (8/9, 88.9%), followed by abdominal discomfort (6/9, 66.7%). Rifaximin was prescribed to the nine patients with positive HBT, but two patients refused to take the medication. Four weeks later, six of the seven patients taking rifaximin (85.7%) reported symptom improvement, and none of them reported adverse events. Conclusions: More than one-third of the patients with inactive intestinal BD who had gastrointestinal symptoms were accompanied by SIBO using HBT. Rifaximin might be an effective and safe drug to treat these patients.

AB - Background and Aims: Many patients with intestinal Behçet's disease (BD) still suffer from gastrointestinal symptoms despite the disease being in endoscopic or radiological remission. Previous studies report that small intestinal bacterial overgrowth (SIBO) can be associated with inflammatory bowel disease. However, there have been no reports about SIBO in patients with intestinal BD. We sought to identify the frequency of SIBO in patients with inactive intestinal BD by hydrogen breath test (HBT) and to investigate the efficacy of rifaximin as a treatment for SIBO. Methods: Twenty-five patients with intestinal BD who had gastrointestinal symptoms even in endoscopic or radiological remission status were enrolled between January 2012 and January 2016. The patients filled out a questionnaire regarding their subjective gastrointestinal symptoms and took an HBT. Patients with positive HBT results were recommended to take 800-mg rifaximin daily for 14 days. Results: Nine patients (9/25, 36%) had a positive HBT test. Eight (8/9, 88.9%) were women, and their mean age was 48.7 years. The most common symptom was abdominal distension (8/9, 88.9%), followed by abdominal discomfort (6/9, 66.7%). Rifaximin was prescribed to the nine patients with positive HBT, but two patients refused to take the medication. Four weeks later, six of the seven patients taking rifaximin (85.7%) reported symptom improvement, and none of them reported adverse events. Conclusions: More than one-third of the patients with inactive intestinal BD who had gastrointestinal symptoms were accompanied by SIBO using HBT. Rifaximin might be an effective and safe drug to treat these patients.

UR - http://www.scopus.com/inward/record.url?scp=85041026884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041026884&partnerID=8YFLogxK

U2 - 10.1111/jgh.13855

DO - 10.1111/jgh.13855

M3 - Article

VL - 33

SP - 375

EP - 379

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 2

ER -